Prostate specific membrane antigen (psma) ligands
AssigneesDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts, Albert-Ludwigs-Universität Freiburg
InventorsMatthias EDER, Ann-Christin EDER
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to the field of dye labelled, preferably fluorescent dye labelled, radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof as well as their use in preoperative PET Imaging and Fluorescence-Guided Surgery of cancers, especially prostate cancer, and metastases thereof.
Claims17
1-15. (canceled)
A PSMA binding ligand or a pharmaceutically acceptable salt or solvate thereof comprising a PSMA binding motif Q, a chelator residue A, a dye group Z and at least one linker LBQ comprising at least one amino acid X1, preferably at least one N-alkylated amino acid, more preferably wherein the amino acid X1 is —N(CH3)—CH2—C(═O)—.
Dependencies are inferred from the claim text.